|
1
|
Lara-Velazquez M, Al-Kharboosh R,
Jeanneret S, Vazquez-Ramos C, Mahato D, Tavanaiepour D, Rahmathulla
G and Quinones-Hinojosa A: Advances in brain tumor surgery for
glioblastoma in adults. Brain Sci. 20:1662017. View Article : Google Scholar
|
|
2
|
Iwadate Y: Epithelial-mesenchymal
transition in glioblastoma progression. Oncol Lett. 11:1615–1620.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bonavia R, Inda MM, Cavenee WK and Furnari
FB: Heterogeneity maintenance in glioblastoma: A social network.
Cancer Res. 71:4055–4060. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. New Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Alonso MM, Gomez-Manzano C, Bekele BN,
Yung WK and Fueyo J: Adenovirus-based strategies overcome
temozolomide resistance by silencing the O6-methylguanine-DNA
methyltransferase promoter. Cancer Res. 67:11499–11504. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang J, Stevens MF and Bradshaw TD:
Temozolomide: Mechanisms of action, repair and resistance. Curr Mol
Pharmacol. 5:102–114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Omar AI and Mason WP: Temozolomide: The
evidence for its therapeutic efficacy in malignant astrocytomas.
Core Evid. 4:93–111. 2010.PubMed/NCBI
|
|
8
|
Neyns B, Tosoni A, Hwu WJ and Reardon DA:
Dose-dense temozolomide regimens: Antitumor activity, toxicity, and
immunomodulatory effects. Cancer. 116:2868–2877. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Garcia-Mayea Y, Mir C, Masson F, Paciucci
R and ME LL: Insights into new mechanisms and models of cancer stem
cell multidrug resistance. Semin Cancer Biol. 60:166–180. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Munoz JL, Walker ND, Mareedu S, Pamarthi
SH, Sinha G, Greco SJ and Rameshwar P: Cycling quiescence in
temozolomide resistant glioblastoma cells is partly explained by
microRNA-93 and −193-mediated decrease of cyclin D. Front
Pharmacol. 10:1342019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cao X, Lu Y, Liu Y, Zhou Y, Song H, Zhang
W, Davis D, Cui J, Hao S, Jung J, et al: Combination of PARP
inhibitor and temozolomide to suppress chordoma progression. J Mol
Med (Berl). 97:1183–1193. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Théry C, Zitvogel L and Amigorena S:
Exosomes: Composition, biogenesis and function. Nat Rev Immunol.
2:569–579. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ratajczak J, Wysoczynski M, Hayek F,
Janowska-Wieczorek A and Ratajczak MZ: Membrane-derived
microvesicles: Important and underappreciated mediators of
cell-to-cell communication. Leukemia. 20:1487–1495. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mathivanan S, Ji H and Simpson RJ:
Exosomes: Extracellular organelles important in intercellular
communication. J Proteomics. 73:1907–1920. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cocucci E and Meldolesi J: Ectosomes and
exosomes: Shedding the confusion between extracellular vesicles.
Trends Cell Biol. 25:364–372. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Azmi AS, Bao B and Sarkar FH: Exosomes in
cancer development, metastasis, and drug resistance: A
comprehensive review. Cancer Metastasis Rev. 32:623–642. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xiao GY, Cheng CC, Chiang YS, Cheng WT,
Liu IH and Wu SC: Exosomal miR-10a derived from amniotic fluid stem
cells preserves ovarian follicles after chemotherapy. Sci Rep.
6:231202016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tanaka S, Hosokawa M, Ueda K and Iwakawa
S: Effects of decitabine on invasion and exosomal expression of
miR-200c and miR-141 in oxaliplatin-resistant colorectal cancer
cells. Biol Pharm Bull. 38:1272–1279. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
O'Brien K, Lowry MC, Corcoran C, Martinez
VG, Daly M, Rani S, Gallagher WM, Radomski MW, MacLeod RA and
O'Driscoll L: MiR-134 in extracellular vesicles reduces
triple-negative breast cancer aggression and increases drug
sensitivity. Oncotarget. 6:32774–32789. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Santos JC, da Silva Lima N, Sarian LO,
Matheu A, Ribeiro ML and Derchain SFM: Exosome-mediated breast
cancer chemoresistance via miR-155 transfer. Sci Rep. 8:8292018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mulcahy LA, Pink RC and Carter DR: Routes
and mechanisms of extracellular vesicle uptake. J Extracell
Vesicles. 3:34022014. View Article : Google Scholar
|
|
22
|
Feng D, Zhao WL, Ye YY, Bai XC, Liu RQ,
Chang LF, Zhou Q and Sui SF: Cellular internalization of exosomes
occurs through phagocytosis. Traffic. 11:675–687. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mincheva-Nilsson L and Baranov V: Cancer
exosomes and NKG2D receptor-ligand interactions: Impairing
NKG2D-mediated cytotoxicity and anti-tumour immune surveillance.
Semin Cancer Biol. 28:24–30. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Soares AR, Martins-Marques T,
Ribeiro-Rodrigues T, Ferreira JV, Catarino S, Pinho MJ, Zuzarte M,
Anjo SI, Manadas B, Sluijter JP, et al: Gap junctional protein Cx43
is involved in the communication between extracellular vesicles and
mammalian cells. Sci Rep. 5:132432015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Scemes E, Spray DC and Meda P: Connexins,
pannexins, innexins: Novel roles of ‘hemi-channels’. Pflugers Arch.
457:1207–1226. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Maes M, Decrock E, Cogliati B, Oliveira
AG, Marques PE, Dagli ML, Menezes GB, Mennecier G, Leybaert L,
Vanhaecke T, et al: Connexin and pannexin (hemi)channels in the
liver. Front Physiol. 4:4052014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Aasen T, Mesnil M, Naus CC, Lampe PD and
Laird DW: Gap junctions and cancer: Communicating for 50 years. Nat
Rev Cancer. 16:775–788. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sin WC, Crespin S and Mesnil M: Opposing
roles of connexin43 in glioma progression. Biochim Biophys Acta.
1818:2058–2067. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gielen PR, Aftab Q, Ma N, Chen VC, Hong X,
Lozinsky S, Naus CC and Sin WC: Connexin43 confers temozolomide
resistance in human glioma cells by modulating the mitochondrial
apoptosis pathway. Neuropharmacology. 75:539–548. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Theis M and Giaume C: Connexin-based
intercellular communication and astrocyte heterogeneity. Brain Res.
1487:88–98. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Caltabiano R, Torrisi A, Condorelli D,
Albanese V and Lanzafame S: High levels of connexin 43 mRNA in high
grade astrocytomas. Study of 32 cases with in situ hybridization.
Acta Histochem. 112:529–535. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Munoz JL, Rodriguez-Cruz V, Greco SJ,
Ramkissoon SH, Ligon KL and Rameshwar P: Temozolomide resistance in
glioblastoma cells occurs partly through epidermal growth factor
receptor-mediated induction of connexin 43. Cell Death Dis.
5:e11452014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Helwa I, Cai J, Drewry MD, Zimmerman A,
Dinkins MB, Khaled ML, Seremwe M, Dismuke WM, Bieberich E, Stamer
WD, et al: A comparative study of serum exosome isolation using
differential ultracentrifugation and three commercial reagents.
PLoS One. 12:e01706282017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Han XJ, Yang ZJ, Jiang LP, Wei YF, Liao
MF, Qian Y, Li Y, Huang X, Wang JB, Xin HB and Wan YY:
Mitochondrial dynamics regulates hypoxia-induced migration and
antineoplastic activity of cisplatin in breast cancer cells. Int J
Oncol. 46:691–700. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Konadu KA, Huang MB, Roth W, Armstrong W,
Powell M, Villinger F and Bond V: Isolation of exosomes from the
plasma of HIV-1 positive individuals. J Vis Exp. 5:534952016.
|
|
36
|
Das A, Banik NL, Patel SJ and Ray SK:
Dexamethasone protected human glioblastoma U87MG cells from
temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and
preventing proteolytic activities. Mol Cancer. 3:362004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fan QW, Cheng C, Hackett C, Feldman M,
Houseman BT, Nicolaides T, Haas-Kogan D, James CD, Oakes SA,
Debnath J, et al: Akt and autophagy cooperate to promote survival
of drug-resistant glioma. Sci Signal. 3:ra812010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chistiakov DA and Chekhonin VP:
Extracellular vesicles shed by glioma cells: Pathogenic role and
clinical value. Tumour Biol. 35:8425–8438. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jia G, Han Y, An Y, Ding Y, He C, Wang X
and Tang Q: NRP-1 targeted and cargo-loaded exosomes facilitate
simultaneous imaging and therapy of glioma in vitro and in vivo.
Biomaterials. 178:302–316. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Goodenough DA and Paul DL: Beyond the gap:
Functions of unpaired connexon channels. Nat Rev Mol Cell Biol.
4:285–294. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Murphy SF, Varghese RT, Lamouille S, Guo
S, Pridham KJ, Kanabur P, Osimani AM, Sharma S, Jourdan J, Rodgers
CM, et al: Connexin 43 inhibition sensitizes chemoresistant
glioblastoma cells to temozolomide. Cancer Res. 76:139–149. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ilvesaro J, Tavi P and Tuukkanen J:
Connexin-mimetic peptide gap 27 decreases osteoclastic activity.
BMC Musculoskelet Disord. 2:102001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Edwards G, Félétou M, Gardener MJ, Thollon
C, Vanhoutte PM and Weston AH: Role of gap junctions in the
responses to EDHF in rat and guinea-pig small arteries. Br J
Pharmacol. 128:1788–1794. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Faniku C, O'Shaughnessy E, Lorraine C,
Johnstone SR, Graham A, Greenhough S and Martin PE: The connexin
mimetic peptide gap27 and Cx43-knockdown reveal differential roles
for connexin43 in wound closure events in skin model systems. Int J
Mol Sci. 19:6042018. View Article : Google Scholar
|
|
45
|
Hombach-Klonisch S, Mehrpour M, Shojaei S,
Harlos C, Pitz M, Hamai A, Siemianowicz K, Likus W, Wiechec E,
Toyota BD, et al: Glioblastoma and chemoresistance to alkylating
agents: Involvement of apoptosis, autophagy, and unfolded protein
response. Pharmacol Ther. 184:13–41. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lu J, Yu M, Lin Z, Lue S, Zhang H, Zhao H,
Xu Y and Liu H: Effects of connexin43 overexpression on U251 cell
growth, migration, and apoptosis. Med Sci Monit. 23:2917–2923.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ito A, Koma Y, Uchino K, Okada T,
Ohbayashi C, Tsubota N and Okada M: Increased expression of
connexin 26 in the invasive component of lung squamous cell
carcinoma: Significant correlation with poor prognosis. Cancer
Lett. 234:239–248. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kalra J, Shao Q, Qin H, Thomas T,
Alaoui-Jamali MA and Laird DW: Cx26 inhibits breast MDA-MB-435 cell
tumorigenic properties by a gap junctional intercellular
communication-independent mechanism. Carcinogenesis. 27:2528–2537.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
McLachlan E, Shao Q, Wang HL, Langlois S
and Laird DW: Connexins act as tumor suppressors in
three-dimensional mammary cell organoids by regulating
differentiation and angiogenesis. Cancer Res. 66:9886–9894. 2006.
View Article : Google Scholar : PubMed/NCBI
|
